1. Home
  2. MNMD vs SWBI Comparison

MNMD vs SWBI Comparison

Compare MNMD & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNMD
  • SWBI
  • Stock Information
  • Founded
  • MNMD 2019
  • SWBI 1852
  • Country
  • MNMD United States
  • SWBI United States
  • Employees
  • MNMD N/A
  • SWBI N/A
  • Industry
  • MNMD Pharmaceuticals and Biotechnology
  • SWBI Ordnance And Accessories
  • Sector
  • MNMD Health Care
  • SWBI Industrials
  • Exchange
  • MNMD Nasdaq
  • SWBI Nasdaq
  • Market Cap
  • MNMD 509.2M
  • SWBI 429.0M
  • IPO Year
  • MNMD N/A
  • SWBI N/A
  • Fundamental
  • Price
  • MNMD $7.17
  • SWBI $8.90
  • Analyst Decision
  • MNMD Strong Buy
  • SWBI Buy
  • Analyst Count
  • MNMD 7
  • SWBI 2
  • Target Price
  • MNMD $26.29
  • SWBI $12.00
  • AVG Volume (30 Days)
  • MNMD 1.2M
  • SWBI 1.3M
  • Earning Date
  • MNMD 08-12-2025
  • SWBI 06-18-2025
  • Dividend Yield
  • MNMD N/A
  • SWBI 5.84%
  • EPS Growth
  • MNMD N/A
  • SWBI N/A
  • EPS
  • MNMD N/A
  • SWBI 0.30
  • Revenue
  • MNMD N/A
  • SWBI $474,661,000.00
  • Revenue This Year
  • MNMD N/A
  • SWBI $8.53
  • Revenue Next Year
  • MNMD N/A
  • SWBI N/A
  • P/E Ratio
  • MNMD N/A
  • SWBI $29.67
  • Revenue Growth
  • MNMD N/A
  • SWBI N/A
  • 52 Week Low
  • MNMD $4.70
  • SWBI $8.38
  • 52 Week High
  • MNMD $10.44
  • SWBI $16.85
  • Technical
  • Relative Strength Index (RSI)
  • MNMD 52.28
  • SWBI 40.96
  • Support Level
  • MNMD $6.40
  • SWBI $8.55
  • Resistance Level
  • MNMD $7.20
  • SWBI $8.91
  • Average True Range (ATR)
  • MNMD 0.43
  • SWBI 0.30
  • MACD
  • MNMD -0.03
  • SWBI -0.10
  • Stochastic Oscillator
  • MNMD 76.03
  • SWBI 19.12

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

Share on Social Networks: